Tilray Brands (TLRY) Q4 2026 earnings review
Beverage Acquisition Transforms Profile, But Cash Burn Lingers
Tilray successfully broke its stagnant growth narrative with a 25% YoY revenue surge in Q4. The catalyst was purely inorganic: the integration of BrewDog catapulted the Beverage segment 61% YoY to $105.6M, officially overtaking Cannabis as the company's largest revenue engine. However, beneath the headline growth and a dramatically reduced net loss (down to $37.9M from last year's $1.2B impairment-driven wipeout), core Cannabis growth has severely decelerated to just 5%. Management is pivoting the narrative toward becoming a diversified global CPG platform, aiming for over $1 billion in FY27 revenue. While the strategic shift protects against Canadian cannabis price compression, the company's deeply negative Free Cash Flow remains a heavy anchor on the bullish thesis.
🐂 Bull Case
With the BrewDog integration, Tilray's pro forma beverage platform reaches $500M. It successfully diversifies the company away from struggling Canadian cannabis, driving an immediate 25% consolidated top-line boost.
International medical cannabis revenue grew 34% in FY26. Tilray's vertically integrated infrastructure (cultivation in Europe plus CC Pharma distribution) provides a solid moat in Germany and surrounding markets.
🐻 Bear Case
Total Cannabis segment revenue decelerated sharply, growing only 5% YoY in Q4. Canadian retail price compression and market saturation are capping organic momentum.
Despite management touting improved 'cash flow excluding working capital,' the actual Adjusted Free Cash Flow was negative $86M for the year. The company is funding its operations through heavy stock dilution and M&A rather than organic cash generation.
⚖️ Verdict: ⚪
Neutral. The transition to a CPG beverage and medical cannabis platform is taking shape, drastically lowering reliance on Canadian recreational sales. However, until Tilray proves it can generate positive absolute Free Cash Flow from this newly acquired scale, the execution risks remain elevated.
Key Themes
BrewDog Fuels Beverage Dominance
The Beverage segment exploded in Q4, hitting $105.6M (+61% YoY) and officially overtaking Cannabis as the primary revenue generator. Management has stabilized the craft beer portfolio and expects the impending Carlsberg U.S. partnership to drastically improve overhead absorption and facility utilization. This inorganic pivot changes the company's entire margin and operational profile.
CC Pharma Extends European Distribution Moat
Distribution net revenue climbed 15% to $85.0M in Q4 (and +21% for FY26). By leveraging the CC Pharma network, which reaches over 16,000 pharmacies in Germany, Tilray guarantees a direct, vertically integrated route to market for its medical cannabis. This infrastructure isolates them from the middle-man margin squeeze affecting their competitors.
Cannabis Growth is Decelerating
While overall revenue grew 25%, the legacy Cannabis division only advanced 5% to $71.5M in Q4. This marks a sharp deceleration from the 19% growth seen in Q3. Gross margins in this segment have flatlined at 44%. Canadian market share retention is coming at the expense of volume growth and pricing power.
Working Capital Destroys Cash Flow Narrative
Management highlighted a 157% improvement in operating cash flow 'excluding working capital'. This is a massive red flag. When including working capital, operating cash flow for the year was deeply negative at $(69.1)M, driven by a $66.4M spike in Accounts Receivable and $26.9M tied up in prepaids. Fast-growing wholesale distribution (CC Pharma) and Beverage integration are severely burning cash.
U.S. Rescheduling Strategy: Medical First
Unlike multi-state operators fighting for recreational retail footprints, Tilray is positioning 'Tilray Medical' specifically for a post-Schedule III clinical environment. The blueprint relies on leveraging global pharmaceutical manufacturing standards, clinical trials, and FDA-compliant pathways to market, bypassing the state-level adult-use regulatory mess entirely.
Hemp-Derived THC Regulatory Risk
Tilray has aggressive growth plans for its hemp-derived Delta-9 (HDD9) beverages in the U.S., but management acknowledges severe macro risk. Potential state-level bans or closures of the Farm Bill loophole in late 2026 threaten the existence of this high-growth adjacent category before it can achieve nationwide scale.
Other KPIs
Despite heavily promoting adjusted profitability, free cash flow remains highly negative, improving only slightly from $(114.1)M in FY25. Capital expenditures of $33M and massive working capital build-ups offset any Adjusted EBITDA gains. The company is not self-funding yet.
A major bright spot on the balance sheet. Tilray systematically reduced its debt load over the year, ending with $235M in cash, restricted cash, and marketable securities against roughly equivalent total debt. This provides the survival runway needed to integrate recent acquisitions without facing immediate credit crises.
Reversing the trajectory from GAAP losses, Adjusted Net Income improved 90% YoY (from $6.5M). This excludes $67.6M in amortization and $45.9M in stock-based compensation, illustrating that while cash operations are stabilizing, historical M&A premiums are still heavily burdening the GAAP bottom line.
Guidance
Accelerating. The midpoint of $71.5M represents a 17% YoY growth rate over FY26's $61.1M, stepping up from the 11% growth achieved this year. Management expects full-year synergy realization from BrewDog and 'Project 420' cost-cutting to drive the bottom line.
Key Questions
Working Capital Drain
Accounts Receivable increased by over $66M this year. Is this primarily tied to extended payment terms in the European distribution business, and when do we expect to see cash conversions normalize?
BrewDog Margin Profile
Beverage gross margins were flat YoY at 38% in Q4 despite the massive revenue injection from BrewDog. What is the expected steady-state gross margin for the combined beverage unit exiting FY27?
Cannabis Plateau
Q4 Cannabis growth slowed to 5% YoY. Have we reached a structural ceiling in the Canadian recreational market, and should we expect this segment to remain flat as capital is entirely redirected to Beverages and Europe?
Path to Absolute Free Cash Flow
Management highlights 'operating cash flow excluding working capital'. But given the persistent $86M Adjusted Free Cash Flow burn, in which fiscal year does Tilray commit to generating positive absolute Free Cash Flow?